Wall Street analysts expect Prothena Corp (NASDAQ:PRTA) to post $6.53 million in sales for the current quarter, Zacks Investment Research reports. Four analysts have provided estimates for Prothena’s earnings, with the highest sales estimate coming in at $25.38 million and the lowest estimate coming in at $200,000.00. Prothena posted sales of $260,000.00 in the same quarter last year, which suggests a positive year over year growth rate of 2,411.5%. The firm is scheduled to issue its next earnings report on Tuesday, May 8th.
According to Zacks, analysts expect that Prothena will report full-year sales of $26.14 million for the current financial year, with estimates ranging from $900,000.00 to $101.55 million. For the next year, analysts anticipate that the company will post sales of $102.33 million per share, with estimates ranging from $25.95 million to $203.80 million. Zacks’ sales averages are an average based on a survey of sell-side research analysts that cover Prothena.
Prothena (NASDAQ:PRTA) last posted its quarterly earnings results on Wednesday, February 14th. The biotechnology company reported ($1.24) EPS for the quarter, topping the consensus estimate of ($1.48) by $0.24. Prothena had a negative return on equity of 33.37% and a negative net margin of 556.84%. The business had revenue of $0.23 million for the quarter, compared to analyst estimates of $0.27 million. During the same quarter in the previous year, the firm earned ($1.41) EPS. The company’s quarterly revenue was up 33.9% compared to the same quarter last year.
Shares of NASDAQ PRTA traded up $0.28 during trading on Friday, hitting $38.25. 30,522 shares of the company were exchanged, compared to its average volume of 540,256. Prothena has a 12-month low of $27.19 and a 12-month high of $70.00. The firm has a market cap of $1,464.29, a PE ratio of -9.41 and a beta of 2.70.
A number of institutional investors and hedge funds have recently modified their holdings of PRTA. New York State Common Retirement Fund raised its holdings in Prothena by 128.1% in the 3rd quarter. New York State Common Retirement Fund now owns 94,900 shares of the biotechnology company’s stock valued at $6,147,000 after buying an additional 53,300 shares during the period. Russell Investments Group Ltd. raised its holdings in Prothena by 10.2% in the 3rd quarter. Russell Investments Group Ltd. now owns 37,325 shares of the biotechnology company’s stock valued at $2,417,000 after buying an additional 3,449 shares during the period. Legal & General Group Plc raised its holdings in Prothena by 15.0% in the 3rd quarter. Legal & General Group Plc now owns 15,761 shares of the biotechnology company’s stock valued at $1,020,000 after buying an additional 2,053 shares during the period. Schwab Charles Investment Management Inc. raised its holdings in Prothena by 5.4% in the 3rd quarter. Schwab Charles Investment Management Inc. now owns 172,578 shares of the biotechnology company’s stock valued at $11,178,000 after buying an additional 8,897 shares during the period. Finally, California Public Employees Retirement System raised its holdings in Prothena by 1.8% in the 3rd quarter. California Public Employees Retirement System now owns 60,700 shares of the biotechnology company’s stock valued at $3,932,000 after buying an additional 1,100 shares during the period.
ILLEGAL ACTIVITY NOTICE: This report was first published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this report on another domain, it was illegally copied and reposted in violation of United States & international copyright legislation. The legal version of this report can be viewed at https://www.chaffeybreeze.com/2018/04/16/6-53-million-in-sales-expected-for-prothena-corp-prta-this-quarter.html.
Prothena Company Profile
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on the discovery, development, and commercialization of novel immunotherapies for the treatment of diseases in the neuroscience and orphan categories. The company is developing antibody-based product candidates that include NEOD001, a monoclonal antibody that is in Phase III and Phase IIb clinical trials for the treatment of AL amyloidosis; PRX002/RG7935 that is in Phase II clinical trial for treating Parkinson's disease and other related synucleinopathies; and PRX004, a monoclonal antibody that is under preclinical development for the treatment of ATTR Amyloidosis.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Prothena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena and related companies with MarketBeat.com's FREE daily email newsletter.